Trial Information
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Sponsor: GOG Foundation Verastem Inc.
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
